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Liquid chromatography (LC) coupled with mass spectrometry (MS) detection is one of the most powerful analytical tools for
organic compound analysis. The advantages of using LC/MS methods over HPLC methods include: selectivity, chromatographic
integrity, peak assignment, structural information, and rapid method development. In this paper, a new liquid chromatography-
tandem mass spectrometry (LC-MS/MS) method has been developed and validated for the determination of bisoprolol in human
plasmasamples,usingmetoprololasinternalstandardandliquid-liquidextractionprocedure.Theassayhasproventobesensitive,
speciﬁc and reproducible, suitable to determine the bisoprolol concentration, following a single oral administration of a 10mg
bisoprolol tablet in 22 healthy volunteers, in the bioequivalence study of Bisoprolol 10mg coated tablets, produced by Antibiotice
S.A. versus Concor 10mg, produced by Merck.
Copyright © 2009 Gabriela Peste et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Bisoprolol fumarate is a synthetic cardioselective β1-
adrenergic blocker. Chemically, bisoprolol fumarate is (±)-
1-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-
methylethyl)amino]-2-propanol(E)-2-butenedioate (2 : 1)
[1]. It possesses an asymmetric carbon atom in its structure
and is provided as a racemic mixture. The S(−) enantiomer
is responsible for most of the beta-blocking activity.
T h eo b j e c t i v e so ft h i sw o r kw e r et od e v e l o pa n dt ov a l i -
dateasimple,accurate,rapidandeconomicLC-tandemmass
spectrometry method for the determination of bisoprolol in
human plasma samples, using liquid-liquid extraction, and
to present some of this method applications.
2.MaterialsandMethods
2.1. Instruments. All analyses were performed using the
Agilent 1100 LC/MSD Trap XCT system. The system com-
penents included the Agilent 1100 Degasser, Agilent 1100
Binary Pump, Agilent 1100 Autosampler, Agilent 1100 Mass
Selective Detector. The Bruker Daltonik software was used
forsystemcontrolanddataacquisition.Ananalyticalbalance
Mettler-Toledo XP56, a Sigma 2–16K centrifuge and a
Vibramax 110 shaker were used for the sample preparation.
The separation was performed using a reverse phase
column (Zorbax SB-C18 Solvent Saver Plus, 3 × 100mm,
3.5μm, supplied by Agilent, USA).
2.2. Reagents. All solvents and other chemicals (acetonitrile,
methanol, sodium hydroxide, tert-butyl methyl ether, water,
formicacid)wereHPLCgradeprovidedbyMerck’sChemical
Co., Darmstadt, Germany. The reference substances of
bisoprolol and metoprolol (internal standard) were supplied
from the USP Pharmacopoeia. The human plasma was
obtained from Center for Blood Drawing and Preservation,
Iasi, Romania.2 Journal of Biomedicine and Biotechnology
2.3. Bisoprolol Stock Solution. Bisoprolol was dissolved
in methanol, obtaining a bisoprolol stock solution of
500μg/mL.
2.4. Metoprolol Stock Solution. The internal standard, meto-
prolol, was dissolved in methanol, obtaining a metoprolol
stock solution of 500μg/mL.
2.5. Solutions for Linearity Response. Eight bisoprolol con-
centrations were prepared in human plasma, covering the
expected range of observed concentrations (1–100ng/mL).
The theoretical concentrations of bisoprolol calibration
standards were 1.0, 2.0, 10.0, 20.0, 40.0, 60.0, 80.0, and
100.0ng/mL.
2.6. Quality Control Samples. Plasma samples having biso-
prolol theoreticals concentrations of 3ng/mL, 25ng/mL and
75ng/mL were considered to be appropriate to be used to
validate the bioanalytical method.
2.7. Samples for Recovery. In order to determine the analyte
and the internal standard recovery from the plasma, water
samplescontainingthesamebisoprololconcentrationsasthe
quality control samples were prepared.
2.8. Samples Preparation. After alkalization with sodium
hydroxide and addition internal standard solution, the
0.250mL plasma sample was extracted with 2mL tert-butyl
methyl ether. The solvent was evaporated using a ﬂow air at
40◦C. The solid residue was dissolved in a 0.250mL mixture
0.1% formic acid solution—acetonitrile (50-50, v/v).
3. Results andDiscussions
3.1. The Development of the LC-Tandem Mass Spectrometry
Method. LC separation of bisoprolol and internal standard,
metoprolol, has been carried out using the mobiles phases
consisting of diﬀerents aqueous solutions and methanol
or acetonitrile as organic phase. Hernardo et al. [2] used
a acetonitrile as organic mobile phase to lead to shorter
retention times and better resolution of the bisoprolol and
internal standard. Formic acid solution as additive in water
was used by Li et al. [3] to improve the sensitivity of MS
detection.
The LC-MS/MS method for determination of bisoprolol
in human plasma samples described in this paper was
performed using a mobile phase consist in mixture 0.1%
formic acid solution (pH 3)—acetonitrile (50-50, v/v). The
LC system was operated at 0.3mL/min, using the binary
pump. The column temperature was 40◦C. The injection
volume was 5μL and represented no more 5% of the total
sample available for injection. Short run times of about
3 minutes were achieved for both bisoprolol and internal
standard, metoprolol. Bisoprolol was eluted at 1.7 minutes
and metoprolol at 1.9 minutes. The peaks of interest were
free from interfering peaks at their respective retention
time.
To minimize undesirable fragmentation voltages were
tested from 80 to 200V. At 100V, the MS response of
bisoprololandmetoprololshowedbothminimalundesirable
fragmentation and highest response.
The mass transition ion-pair was followed as m/z
326.2 → 116.1 for bisoprolol and m/z 268.2 → 191.0, for
metoprolol, as sustained Bhatt et al. [4].
The protonated molecular ion of bisoprolol [M+H]+
(m/z 326.3) was tested to give the highest sensitivity. Based
on the optimization results, m/z 116.2 was selected as
the quantiﬁer ion. Also, the protonated molecular ion of
metoprolol [M+H]+ (m/z 268) was tested and m/z 116.2
was selected as the quantiﬁer ion. We have chosen products
ions with the same m/z value for bisoprolol and metoprolol,
respectively, because a possible suppression eﬀect would
inﬂuence the quantiﬁcation of both the analyte and internal
standard in the same way.
Other mass spectrometric parameters (gas temperature,
g a sp r e s s u r ea n dg a sﬂ o w )w e r ea d j u s t e dt og e tam a x i m u m
signal for bisoprolol. The nebulizing gas ﬂow rate was set at
10l/min, drying gaz temperature at 350◦C, and the capillary
voltage at 4000V. The response of bisoprolol and metoprolol
weremeasuredbyMRMinthepositiveionizationmodewith
a collision energy of 20V.
3.2. Validation of the LC-Tandem Mass Spectrometry Method.
The method was validated according Guidance for Industry:
Bioanalytical Method Validation [5].
The parameters usually examined in the validation
process are selectivity/speciﬁcity, linearity, limit of quantiﬁ-
cation, accuracy and precision, stability.
3.2.1. Selectivity. The reversed-phase HPLC method
described in this paper has been tested for possible
interferences from other plasma factors. Plasma aliquots
from six diﬀerent sources were assessed for analysis in order
to investigate the plasma components behavior.
A si tc a nb es e e ni nFigure 1, no overlapping peaks were
detected at bisoprolol and internal standard retention time,
1.7 minutes and 1.9 minutes, respectively. The bioanalytical
method proved to be selective.
3.2.2. Linearity and Lower Limit of Quantiﬁcation. The
linearity was investigated for a bisoprolol theoreticals con-
centrations range between 1ng/mL and 100ng/mL and the
calibration curve was derived by plotting the peak-height
ratios of the analyte and the internal standard against the
concentration of bisoprolol, using linear regression analysis.
The least-square linear regression revealed that the
relationship was linear in the investigated domain, with a
correlation coeﬃcient of 0.998599, meeting the acceptance
criteria (r2 ≥ 0,990), as it can be seen in Figure 2.
The lower limit of quantiﬁcation, that is, the lowest
standard level with a coeﬃcient of variation less than 20%, is
for bisoprolol 0.990ng/mL with 41.433 signal to noise ratio.
The bioanalytical method proved to be sensitive, allowing a
precise quantiﬁcation of concentrations as low as 1ng/mL
(see Figure 3). Results are presented in Table 1.Journal of Biomedicine and Biotechnology 3
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Figure 1: Chromatogram recorded for blank plasma sample.
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Figure 2: The bisoprolol calibration curve obtained for plasma
samples described in Section 2.5.
3.2.3. Accuracy and Precision. Accuracy of the analitycal
method represents the degree of closeness of the determined
values of an analyte to the nominal/or known true value
declared from an individual sample. The accuracy of a
bioanalytical method is expressed as a percentage of the
nominal value (% nominal).
Precision of the analitycal method represents the degree
of dispersal of the values determined of an analyte, from a
series of samples processed and analyzed individually from
a homogeneous volume of biological matrix. Precision of
a bioanalytical method is expressed as the coeﬃcient of
variation of the concerned series of determinations, CV (%).
The accuracy and precision of this method were cal-
culated for three concentrations of bisoprolol in human
plasma. Six replicate samples having bisoprolol theoreticals
concentrations of 3ng/mL (QC1), 25ng/mL (QC2) and
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Figure 3: Chromatogram recorded for plasma containing biso-
prolol (0.990ng/mL, lower limit of quantiﬁcation) and internal
standard.
75ng/mL (QC3) were injected into the system. Table 2
summarizes the results obtained for the intraday parameters.
The interday precision and accuracy was evaluated also using4 Journal of Biomedicine and Biotechnology
Table 1: Lower limit of quantiﬁcation.
Analyte concentration (ng/mL) 0.990
Conc. (ng/mL) % nominal Signal/noise ratio
0.989 99.945 44.500
1.407 142.094 36.000
0.958 96.802 46.100
1.167 117.863 31.700
1.175 118.723 41.500
1.241 125.400 48.800
N6 6 6
Mean 1.156 116.804 41.433
SD (±) 0.166
CV(%) 14.339
Acceptance criteria
4o u to f6L L Q Cm u s tb e1 0 0 ±20% nominal value.
Mean % nominal 100 ±20%
CV (%) ≤ 20%
Signal/noise ratio ≥ 5
Table 2: Evaluation of intraday precision and accuracy for bisoprolol spiked quality control samples.
Cth = 3ng/mL C th = 25ng/mL Cth = 75ng/mL
Cexp (ng/mL) % nominal Cexp (ng/mL) % nominal Cexp (ng/mL) % nominal
(1) 2.912 98.391 22.524 91.263 69.203 93.468
(2) 3.003 101.439 24.862 100.737 68.525 92.552
(3) 3.262 110.192 23.762 96.281 66.781 90.196
(4) 2.829 95.568 25.189 102.062 76.691 103.580
(5) 3.018 101.960 21.739 88.085 65.844 88.931
(6) 2.854 96.431 21.371 86.593 74.009 99.958
Mean 2.980 100.664 23.241 94.170 70.176 94.781
SD 0.158 1.610 4.268
CV % 5.296 6.927 6.082
Acceptance criteria
67% Total QCs must be 100 ±15% nominal values
50% QCs per level must be 100 ±15% nominal values
Mean % nominal 100 ±15%
CV (%) ≤ 15%
Cth = theoretical concentration. Cexp = experimental concentration. SD = standard deviation. CV % = coeﬃcient of variation
six aliquots for each quality control sample concentration,
prepared and analysed in six diﬀerent days. The results are
presented in Table 3.
Intra-and interday precision of analysis was <8% and
accuracy range was from 94.170% to 102.540%.
The values for the investigated parameters proved to be
lower than the one reported by Oniscu et al. [6], employing a
HPLCmethodwithﬂuorescencedetection.Also,Liuetal.[7]
reported an accuracy ranged from 89.4%–113%, employing
aprecipitationwithacetonitrileprocedureforplasmasample
preparations.
3.2.4. Recovery. Recovery of Bisoprolol was evaluated by
comparing analyte response of six extracted samples of
low, medium, and high quality control samples to those of
six appropriately diluted standard solutions. Mean recovery
values for Bisoprolol are 76.529, 78.479, and 79.863% at low,
medium and high quality control levels, respectively.
For internal standard, mean internal standard response
of eighteen extracted samples was compared to the mean
internal standard responses of eighteen appropriately diluted
internal standard solutions. Mean recovery value for the
internal standard is 90.568%.
3.2.5. Stability Tests. To test stability, a series of standards
samples was prepared from freshly made stock solutions
in the same solvent used for the assay. The lowest and
highest concentration of the quality control (3ng/mL andJournal of Biomedicine and Biotechnology 5
Table 3: Evaluation of interday precision and accuracy for bisoprolol spiked quality control samples.
Cth = 3ng/mL C th = 25ng/mL Cth = 75ng/mL
Cexp (ng/mL) Accuracy (%) Cexp (ng/mL) Accuracy (%) Cexp (ng/mL) Accuracy (%)
(1) 3.015 101.860 24.331 98.586 70.921 95.788
(2) 2.879 97.276 23.332 94.539 77.073 104.097
(3) 3.257 110.048 23.109 93.636 77.932 105.256
(4) 2.964 100.136 24.013 97.297 70.590 95.340
(5) 2.943 99.439 28.411 115.117 75.582 102.083
(6) 3.152 106.480 24.910 100.933 74.865 101.115
Mean 3.035 102.540 24.684 100.018 74.494 100.613
SD 0.142 1.940 3.092
CV % 4.686 7.860 4.151
Acceptance criteria
67% Total QCs must be 100 ±15% nominal values
50% QCs per level must be 100 ±15% nominal values
Mean % nominal 100 ±15%
CV (%) ≤ 15%
Table 4: Stability of analyte following sample processing at room temperature.
Analyte: Bisoprolol
Biological matrix: Human Plasma
Storage condition: 31 Hours at Room Temperature
QC1(3ng/mL) QC3(75ng/mL)
Comparison Samples Stability Samples Comparison Samples Stability Samples
Measured % nominal Measured Measured % nominal Measured
Conc. Conc. Conc. Conc.
2.682 90.611 2.838 80.224 108.352 82.798
2.330 78.719 2.639 82.755 111.771 63.262
3.082 104.134 2.434 78.821 106.457 75.379
2.380 80.392 2.079 79.826 107.815 80.616
2.117 71.504 2.047 91.323 123.343 58.511
2.619 88.475 2.745 84.105 113.595 79.410
N6 6 6 66 6
Mean 2.535 85.639 2.464 82.842 111.889 73.329
SD (±) 0.338 0.338 4.597 10.049
CV(%) 13.314 13.734 5.549 13.704
% Change −2.808 −11.483
Acceptance criteria
67% comparison samples must be 100 ±15% nominal values
Mean % nominal of comparison samples 100 ± 15%
CV (%) ≤ 15%
% Change ± 15%
75ng/mL), including the analyte and internal standard
(when appropiate) were used. Human plasma samples of
each concentration were prepared in enough volume to have
multiple aliquots.The aliquots of each concentration were
processed and quantiﬁed immediately in order to provide
the reference (fresh) values and other six aliquots of each
concentration were processed for the desired tests.
The following subsections present the procedure carried
out and the corresponding results.
(a) Stability of the Analyte after Sample Processing at Room
Temperature. Samples prepared at low (QC1) and high
(QC3) qualitycontrollevelsweresubmitted to theextraction
procedure and kept at room temperature under ambient
laboratoryconditions(stabilitysamples).Acalibrationcurve
and 6 replicates of low and high quality control samples
(comparison samples) were freshly processed and analyzed
with 6 replicates of stability samples in a single run. Concen-
trations were calculated to determine% change over time.6 Journal of Biomedicine and Biotechnology
Table 5: Stability of analyte in biological matrix at room temperature.
Analyte: Bisoprolol
Biological matrix: Human plasma
Storage condition: 4 Hours at Room Temperature
QC1(3ng/mL) QC3(75ng/mL)
Comparison Samples Stability Samples Comparison Samples Stability Samples
Measured % nominal Measured Measured % nominal Measured
Conc. Conc. Conc. Conc.
3.509 118.561 3.540 61.764 83.419 72.020
2.839 95.898 3.502 74.312 100.368 67.462
3.453 116.639 3.281 73.697 99.537 90.117
3.187 107.684 3.514 72.186 97.495 73.715
4.310 145.604 3.616 68.557 92.595 69.225
3.123 105.510 3.688 75.832 102.421 69.012
N6 6 6 6 6 6
Mean 3.403 114.983 3.523 71.058 95.973 73.592
SD (±) 0.506 0.138 5.182 8.405
CV(%) 14.864 3.925 7.292 11.421
% Change 3.522 3.566
Acceptance criteria:
67% comparison samples must be 100 ±15% nominal values
Mean % nominal of comparison samples 100 ± 15%
CV (%) ≤15%
% Change ± 15%
Table 6: Stability of analyte in biological matrix after 3 freeze-thaw cycles at −25 ±10◦C.
Analyte: Bisoprolol
Biological matrix: Human plasma
Storage condition: −25 ±10◦C
QC1(3ng/mL) QC3(75ng/mL)
Comparison samples Stability Samples Comparison Samples Stability Samples
Measured % nominal Measured Measured % nominal Measured
Conc. Conc. Conc. Conc.
3.015 101.860 2.934 70.921 95.788 74.754
2.879 97.276 3.239 77.073 104.097 73.574
3.257 110.048 3.096 77.932 105.256 77.879
2.964 100.136 3.180 70.590 95.340 83.159
2.943 99.439 3.049 75.582 102.083 78.939
3.152 106.480 3.063 74.865 101.115 86.426
N6 6 6 6 6 6
Mean 3.035 102.540 3.093 74.494 100.613 79.121
SD (±) 0.142 0.107 3.092 4.921
CV(%) 4.686 3.454 4.151 6.220
% Change 1.920 6.212
Acceptance criteria
67% comparison samples must be 100 ±15% nominal values
Mean % nominal of comparison samples 100 ± 15%
CV (%) ≤ 15%
% Change ± 15%Journal of Biomedicine and Biotechnology 7
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Figure 4: Average bisoprolol concentrations recorded for the test
and reference drugs in the bioequivalence study performed on 22
healthy volunteers.
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Figure 5: Average dissolved bisoprolol recorded for test and
reference drugs recorded for the in vitro dissolution test.
Bisoprolol is found to be stable for 31 hours at room
temperature under ambient laboratory conditions after
sample processing with % changes (ratio between mean
concentration of stability samples and mean concentration
of comparison samples) of −11.483 and −2.808%. Results
are presented in Table 4.
(b) Stability of Analyte in Biological Matrix at Room Tem-
perature. Samples were prepared at low (QC1) and high
(QC3) quality control levels. Six replicates of low and high
quality control samples were left at room temperature for
approximately 4 hours (stability samples). A calibration
curve and 6 replicates of low and high quality control
samples (comparison samples) were freshly processed with
6 replicates of stability samples and analyzed in a single run.
Concentrations were calculated to determine % change over
time.
Bisoprolol is found to be stable in human plasma for 4
hours at room temperature with % changes of 3.522 and
3.566%. Results are presented in Table 5.
(c) Stability of Analyte in Biological Matrix after 3 Freeze–
Thaw Cycles. Samples were prepared at low (QC1) and high
(QC3) quality control levels, aliquoted and frozen at −25 ±
10◦C. Some of the aliquots of quality control samples were
subjected to three freeze-thaw cycles (stability samples). The
remaining aliquots were not thawed (comparison samples).
Ac a l i b r a t i o nc u r v ea n d6r e p l i c a t e so fl o wa n dh i g hq u a l i t y
control samples (comparison samples) were freshly pro-
cessed with 6 replicates of stability samples and analyzed in
a single run. Concentrations were calculated to determine%
change over freeze-thaw cycles. Bisoprolol is found to be
stable in human plasma after three freeze-thaw cycles with
% changes of 1.920 and 6.212%. Results are presented in
Table 6.
3.3. The Applications of LC-Tandem Mass Spectrometry
Method. The assay has proven to be suitable to determine
the bisoprolol concentration in the bioequivalence study
of Bisoprolol 10mg coated tablets produced by Antibiotice
S.A. (referred to as test drug) versus Concor 10mg coated
tablets produced by Merck (referred to as reference drug). In
Figure 4, average bisoprolol concentrations recorded for 22
volunteersareplottedagainsttimeforbothtestandreference
drugs.
Theconcentrationproﬁlesaresimilarly,ﬁttingtheresults
obtained for the in vitro dissolution test (see Figure 5).
Based on the determined bisoprolol concentrations, the
calculated pharmacokinetic parameters demonstrated that
the drug produced by Antibiotice S.A. is bioequivalent with
the one produced by Merck.
4. Conclusions
LC-tandem mass spectrometry method described and vali-
datedaboveissensitive,accurate,precise,rapid,andeﬃcient.
The developed method can be applied for the determination
of bisoprolol from human plasma samples (e.g., for pharma-
cokinetic parameters).
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